Medipharm Labs Corp (LABS) Fair Value & Analysis
Healthcare · CA · Market cap C$32.9M (≈ $23.8M) · ISIN CA58504D1006
What is Medipharm Labs Corp really worth?
Below-average quality, and trading another 56% above our fair value of C$0.0480.
As of Aug 14, 2026, the fair value of Medipharm Labs Corp is C$0.0480 per share against a price of C$0.0750, so the fair value sits 36% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Aug 14, 2026
From 1 valuation models · updated 23 days ago
Fair value updated Aug 14, 2026, revised from C$0.0484 to C$0.0480 (−0.9%) since Jul 19, 2026. Share price +7.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (C$0.0560). The favourable scenario is already priced in.
- Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.
How to read this chart
60‑month range C$0.0550 – C$0.5400 · fair‑value band C$0.0400 – C$0.0560 · the C$0.0750 price screens above the C$0.0480 fair value. Dashed = 300-day average. As of Aug 14, 2026.
Analysis
Medipharm Labs Corp (LABS) currently trades at C$0.0750, while our model-based Fair Value estimate is C$0.0480, implying the stock looks roughly 56.3% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Over the trailing twelve months, Medipharm Labs Corp generated revenue of C$43.3M at a net margin of −20.2%. Revenue declined 17.1% year over year. It earns a return on equity of −22.3%. The balance sheet holds a net cash position of C$10.6M. Fundamentals as of Aug 14, 2026
Our scenario range runs from C$0.0400 (bear case) to C$0.0560 (bull case); at C$0.0750, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high and 25% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −36%, LABS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when LABS reaches fair value
Put LABS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 14, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally.
Full company description
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower, pre-roll, and other cannabis products. In addition, the company offers cannabis related medical information and services; and cannabis clinic services for patients requiring medical cannabis education and prescriptions. MediPharm Labs Corp. was founded in 2015 and is based in Barrie, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medipharm Labs Corp reported revenue of C$45.1M in FY2025 versus C$21.7M in FY2021, a compound +20.1%/yr. Reported net income was −C$8.3M in FY2025.
LABS screens 56% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 609 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,899 | ₹989.50 | −48% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Medipharm Labs Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Medipharm Labs Corp (LABS) overvalued or undervalued?
What is the fair value of LABS?
What is the quality score of LABS?
What is the price target for Medipharm Labs Corp (LABS)?
What is the Medipharm Labs Corp stock forecast for 2026?
What is the revenue of Medipharm Labs Corp (LABS)?
What is the net profit margin of LABS?
Watch Medipharm Labs Corp in the live analysis
One click puts Medipharm Labs Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.